BioTherapeutics, Inc. Announces Publication of Results from Phase 1 Human Clinical Trial of Abscisic Acid in Healthy Volunteers
BLACKSBURG, VA—August 1, 2019—BioTherapeutics, Inc., (BTI) a clinical-stage biotech company that synergistically combines the power of advanced computational modeling with translational and clinical experimentation to accelerate the development of novel products for precision medicine and health, announced exciting new clinical results of abscisic acid (ABA), its patented, GRAS nutraceutical for glycemic control.
In partnership with Euromed, a leading producer of standardized natural products, BTI published novel clinical findings demonstrating that abscisic acid (ABA) standardized fig (ficus carica) extracts ameliorate postprandial glycemic and insulinemic responses in healthy adults. Results of the recent study are published in the peer-reviewed publication Nutrients.
This study examined the effects of two fig fruit extracts, each administered at two different ABA doses, on glycemic index and insulinemic index to a standard glucose drink. The study found that ABA-enriched fig extracts can produce significant and clinically relevant reductions in postprandial glucose and insulin responses to a high-glycemic index glucose drink.
“We are delighted to report these initial clinical results that validate the prediction of our preclinical studies and support the notion that ABA is a potent nutraceutical for glycemic control in humans,” said Dr. Josep Bassaganya-Riera, Chairman and President of BTI. “Based on these exciting clinical results, BTI and Euromed are planning to advance ABA to Phase 2 clinical studies in prediabetic and Type 2 diabetic patients.”
ABA supplementation in the form of dietary supplements or functional beverages (such as Pervida Sugar Harmony), may serve as a promising, novel nutritional intervention for the management of postprandial glucose homeostasis and help promote healthy blood glucose levels in individuals afflicted with metabolic disorders such as metabolic syndrome, prediabetes, and diabetes.
Details from the study:
- In healthy adults, plasma concentration of ABA increases following oral glucose administration, stimulating peripheral glucose uptake.
- Taken together, these studies suggest that ABA may play an important role in modulating glucose homeostasis in humans.
- Fig fruit extracts enriched in ABA may provide a natural method for controlling blood glucose and insulin fluctuations in metabolic and nutritional disorders, such as hyperglycemia and insulin resistance.
About BioTherapeutics, Inc.
BioTherapeutics, Inc., a clinical-stage biotech company that synergistically combines the power of advanced computational modeling with translational and clinical experimentation to accelerate the development of novel products for precision medicine and health. The company is headquartered in Blacksburg, VA. For more information, please visit www.biotherapeuticsinc.com or contact pio@biotherapeuticsinc.com.
For additional information about Pervida, please email info@pervida.net and visit www.pervida.net.
For additional information about Euromed’s extracts email guy@euromedusa.com and visit http://www.euromed.es.
Contacts
BioTherapeutics, Inc:
Josep Bassaganya-Riera
540.218.2262
jbassaganya@biotherapeuticsinc.com
For Media Requests:
Jennifer Collette
540.218.2262
Related press releases:
Frontiers in Nutrition ABA paper